381231-18-1

381231-18-1 structure

Name: Macimorelin Acetate
Chemical Name: 2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
CAS Number: 381231-18-1
Molecular Formula: C₂₆H₃₀N₆O₃
Molecular Weight: 474.555
Catalog: Signaling Pathways GPCR/G Protein GHSR
Create Date: 2017-04-24 10:00:20
Modify Date: 2025-08-25 20:47:07
Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3].

Name	2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
Synonyms	2-Methylalanyl-N-[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]-D-tryptophanamide JMV 1843 Macimorelin UNII-8680B21W73 D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]- AEZS-130 Macimorelin Acetate

Description	Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> GHSR
Target	GHSR[1]
In Vivo	Macimorelin (5 mg/kg, i.p. twice daily for 2 weeks) decreases the number and duration of seizures in IHKA mouse model[2]. Animal Model: Intrahippocampal kainic acid (IHKA) mouse model[2] Dosage: 5 mg/kg Administration: Intraperitoneal injection (i.p.), twice daily for 2 weeks. Result: Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.
References	[1]. Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093. [2]. An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28(9):3100-3112. [3]. Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34: